Insider Buying: Entrada Therapeutics (NASDAQ:TRDA) Director Acquires 5,000 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Bernhardt Zeiher acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $5.86 per share, with a total value of $29,300.00. Following the purchase, the director owned 5,000 shares of the company’s stock, valued at $29,300. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Entrada Therapeutics Stock Performance

NASDAQ TRDA traded up $0.27 during trading on Thursday, hitting $6.31. The stock had a trading volume of 371,925 shares, compared to its average volume of 307,525. The stock has a market capitalization of $244.95 million, a price-to-earnings ratio of -1.58 and a beta of -0.09. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $16.45. The stock has a 50 day simple moving average of $11.80 and a 200 day simple moving average of $10.89.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.11. The business had revenue of $0.88 million during the quarter, compared to the consensus estimate of $2.92 million. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. On average, sell-side analysts predict that Entrada Therapeutics, Inc. will post -4.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on TRDA shares. Wall Street Zen downgraded shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Roth Mkm set a $10.00 price objective on shares of Entrada Therapeutics in a research note on Friday, May 8th. HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Guggenheim raised shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Hedge Funds Weigh In On Entrada Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC increased its position in shares of Entrada Therapeutics by 9.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock worth $176,000 after acquiring an additional 1,560 shares during the period. Alliancebernstein L.P. increased its position in shares of Entrada Therapeutics by 7.1% during the third quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock worth $141,000 after acquiring an additional 1,620 shares during the period. Great Lakes Advisors LLC increased its position in shares of Entrada Therapeutics by 5.5% during the fourth quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock worth $445,000 after acquiring an additional 2,239 shares during the period. Quadrature Capital Ltd increased its holdings in Entrada Therapeutics by 13.5% during the fourth quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock valued at $209,000 after buying an additional 2,424 shares during the period. Finally, First Trust Advisors LP increased its holdings in Entrada Therapeutics by 3.6% during the second quarter. First Trust Advisors LP now owns 75,120 shares of the company’s stock valued at $505,000 after buying an additional 2,631 shares during the period. 86.39% of the stock is owned by hedge funds and other institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.